



NEWS RELEASE

FOR IMMEDIATE RELEASE

CONTACT:

Michele Rozen
Pure Communications
617-730-8284

Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference

CAMBRIDGE, Mass. – June 6, 2012 – [Catabasis Pharmaceuticals](#), a clinical stage biopharmaceutical company dedicated to the discovery and development of innovative, effective and safe medicines for the treatment of inflammatory and metabolic diseases, today announced that Michael Jirousek, Ph.D., chief scientific officer and co-founder of Catabasis, will present at the Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference to be held June 28-July 1, 2012 at the Harbor Beach Marriott Hotel in Ft. Lauderdale, Fla.

Dr. Jirousek will present in a research panel focused on the role of inflammation and fibrosis in Duchenne Muscular Dystrophy (DMD) at 4:00 p.m. ET on Saturday, June 30, 2012. This interactive panel is part of a special three-part series being presented at this year's meeting focused on clinical trials and the future of this research and treatment for DMD. These panels will feature commentary and insight from parents whose children are or were participating in trials, clinicians who run the trials and from the industry leaders developing these trials.

Dr. Jirousek has also been invited to be a guest speaker in a webinar hosted by PPMD on June 6, 2012 at 1 p.m. ET to discuss the new approaches to treating inflammation in DMD. The webinar can be accessed by visiting www.ReadyTalk.com and providing the participant code 9449985. The audio dial-in can be accessed by dialing 866-740-1260 and providing the access code 9449985.

About Catabasis

Catabasis is a clinical stage company dedicated to the discovery and development of innovative, effective and safe medicines for the treatment of inflammatory and metabolic diseases. The company has assembled a team of passionate and experienced scientists who are committed to improving the lives of patients. Catabasis has developed a pipeline of molecules that produce mechanistic synergy on a targeted pathway. The company's technology platform utilizes pathway pharmacology and has produced a robust pipeline of new chemical entities leveraging its proprietary linker technology. The company was founded in 2008 and is headquartered in Cambridge, Mass. Please visit <http://www.catabasispharma.com> for more information.

###